Laminopathy
(Redirected from Laminopathies)
Laminopathies are a subset of genetic disorders that arise from mutations in genes responsible for encoding proteins of the nuclear lamina. Part of a broader category termed nuclear envelopathies, these diseases relate to defects in the nuclear envelope. Ever since the identification of laminopathies in the late 1990s, extensive research has begun to shed light on the critical role nuclear envelope proteins play in maintaining cellular and tissue integrity in animals.
Symptoms[edit | edit source]
Laminopathies, together with other nuclear envelopathies, manifest in a wide range of clinical symptoms. Notable among these are:
- Skeletal and cardiac muscular dystrophies
- Lipodystrophy and diabetes
- Dermal and neuropathic conditions
- Dysplasia
- Leukodystrophy
- Progeria (premature aging)
While most symptoms tend to emerge postnatally, specifically during childhood or adolescence, certain laminopathies might result in premature mortality. For instance, mutations within the lamin B (LMNB1 gene) can prove lethal either at or before birth.
Genetics[edit | edit source]
Fundamentally, individuals diagnosed with a classic laminopathy exhibit mutations in the LMNA gene, which encodes for lamin A/C. Later discoveries have linked mutations in the lamin B (LMNB2 gene) and genetic defects that alter lamin B abundance to laminopathies. Other implicated genes in nuclear envelopathies encode for lamin-binding proteins such as:
- Lamin B receptor (LBR gene)
- Emerin (EMD gene)
- LEM domain-containing protein 3 (LEMD3 gene)
- Prelamin-processing enzymes like the zinc metalloproteinase STE24 (ZMPSTE24 gene)
Laminopathies can stem from both recessive and dominant alleles, with rare instances of de novo mutations generating dominant alleles that may prevent carriers from reproducing before they perish. The most prevalent nuclear envelopathy in humans is the Emery-Dreifuss muscular dystrophy, which is traced back to an X-linked mutation in the EMD gene encoding for emerin. This condition affects approximately 1 in 100,000 individuals.
External links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD